✦ LIBER ✦

Imatinib Mesylate in the Treatment of Chronic Myelogenous Leukemia

✍ Scribed by Gautam Borthakur; Jorge E. Cortes

Book ID: 111835350
Publisher: Carden Jennings Publishing
Year: 2004
Tongue: English
Weight: 108 KB
Volume: 79
Category: Article
ISSN: 0925-5710
DOI: 10.1532/ijh97.04054

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-utility analysis of imatinib mesyla

Cost-utility analysis of imatinib mesylate for the treatment ofchronic myelogenous leukemia in the chronic phase

✍ Emma Warren; Sue Ward; Adam Gordois; Paul Scuffham 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 783 KB

Imatinib Mesylate: : A New Pill for Chro

Imatinib Mesylate: : A New Pill for Chronic Myelogenous Leukemia

✍ Kavita K. Parmar; Reginald S. King 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

Response of concomitant chronic myelogen

Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate

✍ Ju-Yoon Yoon; Rajat Kumar; Raquel Aloyz; James B. Johnston 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 162 KB

Resolution of leukemic retinopathy follo

Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia

✍ John B Christoforidis; Daniel J DeAngelo; Donald J D’Amico 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 100 KB

Hematologic and Cytogenetic Responses to

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

✍ Kantarjian, Hagop; Sawyers, Charles; Hochhaus, Andreas; Guilhot, Francois; Schif 📂 Article 📅 2002 🏛 Massachusetts Medical Society 🌐 English ⚖ 173 KB

Persistent neutropenia in chronic myelog

Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate

✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.